Πέμπτη 8 Μαρτίου 2018

Pacritinib vs Best Available Therapy in Patients With Myelofibrosis

This phase 3 randomized clinical trial compares the efficacy and safety of Janus kinase 2 inhibitor pacritinib with that of best available therapy, including ruxolitinib, in patients with myelofibrosis and thrombocytopenia.

from Cancer via ola Kala on Inoreader http://ift.tt/2FzEorg
via IFTTT

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου